| Who is it? | CEO and Founder, Regeneron Pharmaceuticals |
| Birth Year | 1953 |
| Birth Place | Tarrytown, New York, United States |
| Leonard Schleifer age | 70 YEARS OLD |
| Residence | Tarrytown, New York |
| Education | Cornell University (BS) University of Virginia (MD PhD) |
| Occupation | Doctor Businessman |
| Known for | Founder and CEO of Regeneron |
| Spouse(s) | Harriet Partel Schleifer |
| Children | Adam Schleifer David Schleifer |
| Parent(s) | Florence Schleifer Charles Baker Schleifer |
Leonard Schleifer, renowned as the CEO and Founder of Regeneron Pharmaceuticals in the United States, is expected to amass a net worth of $2.6 billion by 2024. Schleifer's exceptional leadership and entrepreneurial skills have propelled Regeneron Pharmaceuticals to the forefront of the pharmaceutical industry, further solidifying his financial success. Under his visionary guidance, Regeneron has revolutionized the development of therapeutic drugs and pioneered innovative treatments for various diseases. Schleifer's net worth reflects not only his professional achievements but also his profound contribution to the medical field and society as a whole.
Noticing that the biotechnology company Genentech was conducting state-of-the-art research but not on diseases of the nervous system, he determined to get into the biotechnology Business. After rebuking Gilman's efforts to recruit him as an academic, he found a sponsor in George Sing, a venture capitalist at Merrill Lynch, and obtained $1 million in seed capital. He also recruited George Yancopoulos, a 28-year-old scientist, to be his partner, and in 1988 they founded Regeneron Pharmaceuticals. After several years of trying to recruit research doctors many of whom preferred to work in academia or for large corporations, they developed their first drug to treat Lou Gehrig’s disease. It was a failure as was their second drug to treat obesity. Thereafter, they invited the former Merck & Co. CEO Roy Vagelos to be the chairman of their company to help turn the company around. He implemented two strategic changes: only invest in drugs in which the biology of the disorder is fully understood; and do not underestimate the importance of human testing to ensure that what works in the laboratory will also work in the real world.
As CEO of Regeneron, Schleifer oversaw the "approval and growth of high-priced drugs." In 2011, Regereron's first successful drug was, Eylea, for age-related macular degeneration. Eylea prevented leaky blood vessels in the eye from causing blindness. He licensed the drug to Aventis which was then bought by Sanofi which had no interest in the eye drug. Sanofi, in order to get out of its commitment, paid Regeneron $50 million and ceded the rights back to Regeneron. The drug was a blockbuster generating $838 million in its first full year and sales increased 55% to $1.3 billion in 2013 making Schleifer a Billionaire. In 2014 Eylea grossed $1.735 billion.
As CEO Schleifer received a total compensation of $41,965,424 in 2014. According to the "annual collaborative report" from Equilar and The New York Times, Schleifer ranked 15th in the May 2015 list of "200 highest-paid CEOs of large publicly traded companies." He ranked first in the list of biopharmaceutical executives with the highest total compensation.
